Fulgent Genetics, Inc.
General ticker "FLGT" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $661.6M (TTM average)
Fulgent Genetics, Inc. does not follow the US Stock Market performance with the rate: -8.6%.
Estimated limits based on current volatility of 1.7%: low 19.35$, high 20.01$
Factors to consider:
- Total employees count: 1344 (+2.4%) as of 2025
- US accounted for 91.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Cybersecurity threats, Regulatory and compliance, Customer concentration, Acquisition/divestiture risks, Liquidity and credit risks
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.10$, 27.76$]
- 2026-12-31 to 2027-12-31 estimated range: [13.49$, 25.29$]
Financial Metrics affecting the FLGT estimates:
- Positive: with PPE of 65.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.30 <= 0.28
- Positive: Industry inventory ratio change (median), % of 0.16 <= 0.27
- Positive: Interest expense per share per price, % of 0.01 <= 0.75
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 13.48 > -0.64
Short-term FLGT quotes
Long-term FLGT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $289.21MM | $283.47MM | $322.67MM |
| Operating Expenses | $484.74MM | $357.39MM | $413.77MM |
| Operating Income | $-195.53MM | $-73.92MM | $-91.10MM |
| Non-Operating Income | $21.44MM | $21.96MM | $21.07MM |
| Interest Expense | $0.49MM | $0.17MM | $0.07MM |
| R&D Expense | $41.44MM | $48.82MM | $53.91MM |
| Income(Loss) | $-174.09MM | $-51.96MM | $-70.03MM |
| Taxes | $1.15MM | $-8.14MM | $-8.39MM |
| Net Income(Loss)* | $-167.82MM | $-42.71MM | $-60.51MM |
| Stockholders Equity | $1,136.10MM | $1,133.23MM | $1,111.99MM |
| Inventory | $5.83MM | $8.38MM | $10.60MM |
| Assets | $1,235.33MM | $1,219.96MM | $1,213.53MM |
| Operating Cash Flow | $27.00MM | $21.06MM | $-101.64MM |
| Capital expenditure | $22.21MM | $40.31MM | $22.57MM |
| Investing Cash Flow | $38.90MM | $-58.35MM | $111.37MM |
| Financing Cash Flow | $-47.78MM | $-4.85MM | $-14.79MM |
| Earnings Per Share** | $-5.63 | $-1.41 | $-1.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.